Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Consensus Interferon-Alpha Plus Interferon Gamma-1b in HCV Non-Responders
NCT00084279Phase 2Completed
- Sponsor
- InterMune
- Start
- Apr 2004
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised trial of interferon alfacon-1 and interferon gamma-1b in hepatitis C (HCV) (2 arms), sponsored by InterMune. Primary endpoint: Virologic response defined as >2 log (base 10) reduction in HCV RNA at 72 weeks. Started Apr 2004; status: completed.
02
Drugs
interferon alfacon-1interferon gamma-1b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00084279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084279.